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Abstract 
Background: Multimodal therapy is used increasingly in 
advanced gastrointestinal tumors. Potential benefits of using 
an intraoperative adjuvant herapy during laparoscopy for 
cancer have been documented in animal studies. The aim of 
this study was to develop adevice that could deliver such an 
intraoperative drug therapy. 
Methods: We developed a micropump suitable for mini- 
rnally invasive surgery procedures that allowed microdrop- 
lets of therapeutic substance to be distributed into the pneu- 
moperitoneum (CO2), creating a "therapeutic pneumoperi- 
toneum." A closed-loop control system regulates drug 
delivery according to the gas flow. In vitro, the micropump 
is able to aerosolize various aqueous and ethanol solutions, 
including cytostatic and bacteriostatic drugs and adhesion- 
modulating agents. The size of the microdroplets has been 
optimized to prevent visual artifacts. 
Results: The micropump was tested in an animal model 
(pig). The system was inserted into a 5-ram trocar. After 
insufflation of a 12-ram CO 2 pneumoperitoneum, laparo- 
scopic sigmoid colon resections could be performed with no 
:~pecial difficulties. No fog developed, and no system- 
related complication was observed. At autopsy, the active 
principle was distributed to all exposed peritoneal surfaces. 
Conclusions: As opposed to conventional peritoneal wash- 
ing, therapeutic pneumoperitoneum reaches the entire peri- 
toneal surface, allowing an optimal drug distribution. Drug 
diffusion into the tissues i enhanced by the intraperitoneal 
pressure. Precise determination of the instantaneous and to- 
tal drug quantity is possible. Therefore, this drug delivery 
system has several advantages over conventional irrigation. 
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The automated carbon dioxide (CO2) pneumoperitoneum, 
introduced by Serum [21] in 1980, is now the accepted 
standard for exposing the abdominal cavity during laparo- 
scopic procedures. In the meantime, it has been claimed that 
CO 2 pneumoperitoneum hasseveral side effects. In particu- 
lar, it recently has been documented that CO 2 stimulates 
tumor growth after laparoscopy for cancer [14], and that it 
increased bacterial translocation i peritonitis [3]. 
Gasless laparoscopy has been proposed as a solution for 
these side effects [5, 17, 26], but limited exposure might 
prevent he use of this technique for advanced laparoscopic 
procedures such as colonic resections. Alternative types of 
gas have been proposed for expanding the abdominal cav- 
ity. In particular, helium has inhibitory effects on tumor 
growth [8, 12], but this gas is not resorbable and therefore 
carries a potential risk of lethal gas embolisms in the case of 
venous lesions [4, 22]. 
We propose a different solution to prevent some side 
effects of CO2 without increasing the technical difficulty of 
the surgical procedure nor the risks for the patient. The CO 2 
might be used not only as an abdominal wall expander, but 
also as a drug carrier, introducing the novel concept of 
"therapeutic pneumoperitoneum." Thus, therapeutic pneu- 
moperitoneum not only might prevent the side effects from 
CO z, but also might improve the results of minimally inva- 
sive surgery in selected indications by allowing intraopera- 
tive multimodal therapy. Arguments for using a drug in 
aerosol form carried by the insuffiation gas rather than as a 
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~ Micropump ~ ~:~ 
Fig. 1. The micropump is inserted between the gas insufflator and the abdominal cavity of the patient. 
Fig. 2. Prototype of the vapodzator with three spraying units (A) in this case. The CO2 tube (B) is connected to the micropump (C) that has been inserted 
into a 5-ram trocar (D). Condensation f microdroplets is visible downstream (E). 
peritoneal wash are a better distribution of the drug in the 
abdomen and better drug diffusion into the tissues by the 
pressurization of the peritoneal cavity. 
To create such a therapeutic pneumoperitoneum, an in- 
tracavitary drug delivery device suitable for minimally in- 
vasive surgery procedure is necessary. After designing and 
manufacturing such a prototype, we performed in vitro ex- 
periments to determine the behavior of the micropump with 
various kinds of solutions and to assess the flow rate, the 
influence of viscosity, the optimal delivery rate, and the 
optimal droplet size. Then we conducted in vivo experi- 
ments to test the intra-abdominal delivery rate and the peri- 
toneal coating uniformity, and to detect possible unexpected 
events caused by the device during surgical procedures. The 
results of these experiments are reported in the current fea- 
sibility study. 
Material and methods 
The current invention is an ntracavitary drug delivery device suitable for 
minimally invasive surgery procedures, allowing the creation of a thera- 
peutic pneumoperitoneum. The eft'ieiency of the therapeutic pneumoperi- 
toneum depends on the activity of the substance (which depends on the 
composition), the place of impact (i.e.. the place at which it maycarry out 
its activity), dose repeatability (i.e., the fact at he volume of each dose 
remains constant), and, if indicated, the concentration repeatability (mean- 
ing that the drug flow remains constant with the gas flow), 
the operation the amount of therapeutic substance that has been adminis- 
trated to the patient. 
Results 
In vitro trial 
The aim of the in vitro trials was to work out the kind of 
solutions including that can be aerosolized by. the micro- 
pump, the influence of viscosity, the maximal flow, and the 
optimal droplet size. 
Kinds of solutions. We have shown that the micropump is 
able to aerosolize liquids such as water, ethanol, and various 
solutions including these: 
9 taurolidine (Taurolin, Geistlich, Wolhusen, Switzerland) 
9 5-fluorouracil (Wyeth-Lederle, Wolfrathshausen, Ger- 
many) 
9 mitoxanthronhydrochlorid (Novantron, Wyeth-Lederle, 
Wolfrathshausen, Germany) 
9 betadine (Betaisodona, Mundipharma, Limburg, Ger- 
many), with some limitations due to PVP adhesive char- 
acteristics. 
These solutions have pH values between 6.0 and 9.0. 
Design of the prototype 
The device consists of two elements: a micropump and a monitor. The 
micropump delivers the drug (in liquid form) as a dispersion f atomized 
droplets, thanks to the incorporated monodispersive spray device. The 
device is located between a gasinsufflator and the body cavity where the 
surgery is to be performed (Fig. 1), which allows the device to aerosolize 
microdroplets of the therapeutic substance into the pneumoperitoneum. 
The liquid is aerosolized by excitation of a piezoelectric element. 
Figure 2 shows in detail a prototype of the rnicropump built directly 
into a commercially available (Endopath, Ethicon Endosurgery, Norder- 
stedt, Germany) 5-mm trocar. The monitor is placed in the vicinity of the 
gas insufflator. Flow rate, concentration, and amount of drug delivery are 
regulated according to the gas flow in a closed-loop control system. The 
control system allows for weighted-factor drug delivery according to the 
patient's condition and the level of intervention (EPO application 
95908180.3). It is therefore possible to know precisely at each moment f 
Influence of viscosity. Because all the aforementioned so- 
lutions have low viscosity coefficients (<300 centipoises), 
we were not able to observe any negative influence of vis- 
cosity. 
Maximalflow. Gas and drug flow calculations were based 
on measurements u ing input and output pressure sensors 
for termination of the differential pressure. Flows be- 
tween 6 and 20 ixl/s were achieved with one spraying unit 
(Fig. 3), Because of a redundancy of spray devices (e.g., 
three in the current prototype), a continuous reliable opera- 
tion of the drug delivery system and an enhanced peak flow 
were obtained in vitro. 
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Fig. 3. Volume (and quantity) of drug aerosolized bythe micmvaporisator can be determined precisely by integrating the surface under the flow curve. 
Fig. 4. Distribution of3 ml of a 50% methylene blue solution after 30 rain pneumoperitoneum, showing adiffuse staining with an enhanced concentration 
in the axis of the trocaz (arrow) where the tumor is located. 
Droplet size. A microdroplet size smaller than 10 p~m was 
selected to allow maximal diffusion. It was observed that 
droplet size is inversely proportional to the excitation fre- 
quency of the monodispersive spray unit. 
In vivo trial 
The decision to use tanro.lidin in the current animal trial was 
based on a study of Jacobi [11] showing that application of 
taurolidin in the rat model was able to reduce significantly 
the incidence of port-site recurrences. Furthermore, toxicity 
of taurolidin in the pig is known to be low (data on file, 
Geistlich, Wolhusen, Switzerland). 
Surgical procedure. After official permissions were ob- 
tained, two German land race pigs (weight, 21.3 and 20.4 
kg, respectively) were anesthetized using routine protocols. 
Pneumoperitoneum of 12 mmI-Ig was established using a 
Veres needle. At the beginning of the procedure, a further 
5-ram commercially available trocar (Endopath) was in- 
serted into the left upper quadrant, and the introducer was 
replaced by the micropump. A laparoscopically assisted re- 
section of the sigmoid colon with transanal double-stapling 
was performed in both animals, using a four-trocar tech- 
nique. Operating times were 90 and 97 min, respectively. 
The CO z volumes were 156 and 195 liters. (An artificial 
leak was created by opening a valve on the right lower 
trocar.) During the operation, a solution of taurolidin 2% 
was aerosolized into the abdominal cavity. 
Drug distribution. Distribution of the active principle 
within the abdominal cavity was assessed by aerosolizing 3 
ml of a 50% methylene blue solution into a pig cavader after 
installation of a pneumoperitoneum of 12 mmHg for 30 
min. This assay showed a dispersion of the microdroplets 
within the entire abdominal cavity, including the anterior 
abdominal wall where trocar sites had been placed (Fig. 4). 
It is important that nonexposed surfaces uch as the bursa 
omentalis and the inferior liver aspect were not stained. The 
trocars were not moved during this experiment. As ex- 
pected, the distribution was not homogeneous, and staining 
was enhanced in the vicinity and axis of the trocar where the 
micropump had been introduced. 
Unexpected problems. Both surgical procedures, performed 
by two experienced laparoscopic surgeons, showed no tech- 
nical difficulties. In particular, vision was not impaired. 
Cardiorespiratory instability was observed in both animals 
by the anesthesiologist, which could be explained by the 
hypotonic nature of the 2% taurolidine solution that should 
have been corrected with saline. 
As soon as the relative humidity in the intraperitoneal 
cavity approached 100%, the micropump was not able to 
aerosolize any longer. For this reason, we had to create a 
continuous artificial gas leak through a trocar tap and a 
usual gas fine. This allowed the micropump to function 
throughout the procedure, but modified the standard lapa- 
roscopic procedure, in which the gas flow usually is inter- 
rupted in the absence of any gas leak. 
Discussion 
We propose the novel concept of "therapeutic pneumopefi- 
toneum," defined as the association of a cartier gas such as 
CO 2 with an aerosolized therapeutic substance. 
Results show that it is possible to create a therapeutic 
pneumoperitoneum with the drug delivery device used in 
the current study. It was possible simultaneously toperform 
resections of the sigmoid colon with no special surgical 
difficulty. This study was a feasibility test in a large animal 
model. Positive or negative target effects of drugs were not 
assessed at this stage of development. Therefore, this study 
provides no proof of the interest hat therapeutic pneumo- 
peritoneum may have in clinical practice. Nevertheless, 
therapeutic pneumoperitoneum hasseveral interesting prop- 
erties related to intraperitoneal pharmacokinetics. 
The pharmacokinetic problems in peritoneal drug ad- 
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ministration were reviewed recerltly by Dedrick and Fless- 
net {7]. Both theory and clinical studies demonstrate hat 
drug concentrations in the peritoneal cavity can greatly ex- 
ceed concentrations in the plasma after intraperitoneal d- 
ministration. This regional advantage has been associated 
with clinical activity [2]. Two pharmacokinetic problems 
appear to limit the effectiveness of intraperitoneal therapy: 
poor tumor penetration by the drug and incomplete imga- 
tion of serosal surfaces by the drag-containing solution. In 
both respects, the current invention might have major ad- 
vantages over conventional irrigation. 
Exposure of the peritoneal surface 
Various observations in experimental nimals uggest lim- 
ited exposure of the peritoneal surface under conditions of 
peritoneal dialysis. In general, definitive studies have not 
been conducted on the potential pentone,nl surface area of 
human subjects. The likelihood exists that mnch of the re- 
sidual tumor burden after surgery is untreated or under- 
treated by conventional intraperitoneal irrigation. If the 
peritoneal surfaces are not exposed to drug-containing so- 
lutions or if they are inadequately exposed, then the ratio- 
nale for regional administration is compromised [7]. Theo- 
retical considerations suggest that the therapeutic pneumo- 
peritoneum should be capable of carrying microdroplets of
active substances to all exposed peritonteal surfaces. These 
considerations were confttmed by the current pilot study 
conducted in two animals, in which all exposed peritoneal 
surfaces were stained by methylene blue, suggesting that the 
active principle is distributed throughout the abdomen. 
Increasing drug penetration 
Obtaining large increases in the 6ssue penetration of a drug 
might be difficult. Both theoretical predictions and experi- 
mental measurements suggest very limited penetration of 
drugs into tissues, including tumors adjacent to the perito- 
neal cavity. Interestingly, introducing dialysis solution into 
the peritoneal cavity of rats and raising the intraperitoneal 
pressure from 0 to 4 cm H20 caused the extraceltular space 
of the anterior abdominal wall to double. This likely in- 
creased the effective diffusivity [71. However, only limited 
clinical data are available to substantiate hese preliminary 
observations [13]. In this respcct also, thcrapeutic pneumo- 
peritoneum has theoretical advantages over intraperitoneal 
irrigation, by applying inu'a-abdominal pressures of 12 to 15 
mmHg (16 to 20 cm HzO). 
Therapeutic pneumoperitoneum hasnumerous potential 
applications, in particularly in the following fields. 
Prevention of local recurrence after cancer laparoscopy 
The main causes of local recurrence are intraoperative tu- 
mor cell implantation and inadequate xcision of the pri- 
mary tumor or the draining lymph nodes [1]. Because they 
are breaking the natural barrier formed by mesothelium and 
hylumnic acid [15], peritoneal wounds [25] such as those of 
trocar sites [14] or anastomoses are major causes of recur- 
rence. The presence of gowth factors and other cytokines in 
surgical wounds ",after cancer resections might stimulate 
growth of minimal residual disease. Avoidance of unneces- 
sary surNcal trauma by gentle techniques, control of spilled 
cells by intraoperative locoregional cytostatic drug delivery, 
and treatment of peritoneal wounds by aerosolizing coating 
agents therefore could reduce the local recurrence rate. 
Prevention of port-site recurrences 
Jacobi et al, [11] have shown that intraperitoneal lavage 
with taurolidine in cancer laparoscopy was able to reduce 
markedly the incidence of port-site recurrences in the rat 
model. At this point, the micropump has been shown to 
aerosolize a 2% taurolidine solution, and because the thera- 
peutic substance reaches the anterior and lateral abdominal 
walls in the current animal model, it can be hypothesized 
that a preventive effect will be achieved. Therapeutic pneu- 
mopefitoneum also might be used in thoracoscopy. Because 
port-site recurrences also have been described uring such 
procedures [9], aerosolization of taurolidine [16] or other 
hyaluoronates might be indicated as well. 
Intraperitoneal nd intrapIeural chemotherapy 
The response of established carcinoma or sarcoma implants 
to intraperitoneal nd intrapleural chemotherapy is multi- 
factorial. Two of the factors that influence the pharmacoki- 
netics of intraperitoneal drugs are pressure [13] and heat 
[23]. Application of an intraperitoneal hyperpressure such 
as pneumoperitoneum in taparoscopy and heated CO2 might 
be a promising approach to increase the drug diffusion into 
the tumor and to enhance the efficiency of intraperitoneal 
chemotherapy. These points deserve further research be- 
cause in the case of colorectaI adenocarcinoma there are 
insufficient data on which to base a clear-cut conclusion 
concerning real benefits [t8J. 
Modulation of tumor immunogeneity 
In the animal model, stress factors such as both'rate (asso- 
ciated or not with heat) in peritoneal carcinosis of colorectal 
origin have been shown to enhance tumor immunogenicity. 
In the rat model, immunomodulation followed by passive 
immunotherapy using intraperitoneal interleukin-2 (IL-2) 
application achieved some complete tumor esponses in es- 
tablished peritoneal carcinosis [19, 20]. 
Benign disease 
Other possible applications of therapeutic pneumoperito- 
neum concern benign disease such as intra-abdorninal or
intrapleural infections and prevention of postoperative ad- 
hesions. Because ithas been shown that intraoperative bupi- 
vaeain irrigation reduces both frequency and intensity of 
shoulder pain after laparoscopic procedures [6], therapeutic 
pneumoperitoneum also might be ~zsed for postoperative or 
even intraoperative analgesia. 
It is important o note, however, that technical chai- 
lenges remain. To aerosolize drug solutions into the gas 
55 
stream, it was necessary to maintain a gas flow throughout 
the procedure, so large volumes of C02 were used. Tech- 
nically, this was possible by opening a trocar tap and di- 
verting the therapeutic pneumoperitoneum over a usual line 
into a special waste recipient. Alternatively, the gas might 
be diverted into an active coal filter. This might have caused 
some degree of hypothermia n the patient. 
Despite the laminar air flow in modem operating rooms, 
to prevent exposure of the surgical team to potentially haz- 
ardous drugs, no therapeutic pneumoperitoneum should be 
allowed to escape into the environment during the proce- 
dure. Such gas leaks should be prevented during laparoscop- 
ic cancer surgery because they appear to promote implan- 
tation and ~owth of free intraperitoneal tumor cells at port 
sites [24] and might be toxic when tissue has been cauter- 
ized [10]. In the particular case of intraperitoneal chemo- 
therapy using cytostatic drugs, it might be necessary for the 
operating team to leave the room during the application of 
the drug (e.g., at the end of the procedure). 
Using monopolar cautery in the presence of aqueous 
taurolidine solution was possible with no limitation. Nev- 
ertheless, further study using flammable solvents such as 
ethanol is necessary to identify potential hazards. 
In summary, we introduce the novel concept of "thera- 
peutic pneumoperitoneum" in laparoscopic and thoraco- 
scopic surgery to prevent some side effects of CO 2 pneu- 
moperitoneum without increasing the difficulty of the sur- 
gical procedures nor the risks to the patient. Expected and 
unexpected effects of various drugs now need to be assessed 
in appropriate studies. These might be exciting fields of 
research for engineers, pharmaceutical companies, oncolo- 
gists, and laparoscopic surgeons. 
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